The clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 nuclease (Cas9) system is a powerful genome-editing tool for both chromosomal and extrachromosomal DNA. DNA viruses such as Epstein-Barr virus (EBV), which undergoes episomal replication in human cells, can be effectively edited by CRISPR/Cas9. We have demonstrated targeted editing of the EBV genome by CRISPR/Cas9 in several lines of EBV-infected cells. CRISPR/Cas9-based mutagenesis and genome engineering of EBV provides a new method for genetic analysis, which has some advantages over bacterial artificial chromosome-based recombineering. This approach might also prove useful in the cure of EBV infection. In this chapter, we use the knockout of the BART promoter as an example to detail the experimental procedures for construction of recombinant EBV in human cells.
Introduction
Genetic studies are important to all areas of biology. In virology, targeted mutation of particular genetic elements on the viral genome helps to understand their function. In the early years, genomes of herpesviruses were engineered using homologous recombination in eukaryotic cells [1] [2] [3] [4] . Subsequently, the successful cloning of herpesviral genomes into bacterial artificial chromosomes (BACs) greatly facilitated viral genome manipulation in prokaryotic cells [5] [6] [7] [8] . However, in γ-herpesviruses including EBV and Kaposi sarcoma-associated herpesvirus, the titers of viruses recovered from BAC-transfected producer cell lines are usually very low for unknown reasons, and some transfectants even lose their ability to support lytic viral replication [7] . The low efficiency in generating high-quality γ-herpesvirus producing cell lines has become the bottleneck issue in the use of EBV BAC in the field [7] . Intensive screening of stable cells is required to obtain high-quality EBV producing cell lines and this hinders the application of EBV BAC.
In order to provide an alternative method for mutagenesis and genome engineering of EBV, we harnessed the emerging CRISPR/ Cas9 technology for targeted editing of the EBV genome. CRISPR/ Cas9 was originally discovered as part of the adaptive immune system in bacteria but has now been developed into a powerful method for double-strand break (DSB)-induced genome editing in eukaryotic cells [9, 10] . The EBV genome exists in infected cells as multicopy episomes [11] and this poses a unique challenge for CRISPR/Cas9 editing. Whether the multicopy EBV episome could be efficiently cleaved by CRISPR/Cas9 is one major concern and how the correctly edited version of the EBV genome might be separated from predominantly unedited viral DNA is another critical issue. In this regard, we have not only demonstrated the feasibility of CRISPR/Cas9 editing of the EBV genome but have also designed and tested different approaches to isolate the correctly edited recombinant EBV [12] .
In this chapter, we detail how we harnessed CRISPR/Cas9 to edit the EBV genome in human cells. First, we describe the steps and criteria for optimal guide RNA (gRNA) design for EBV editing (see Subheading 3.1). Second, we provide the step-by-step procedures for CRISPR/Cas9 editing of the EBV genome in mammalian cells (see Subheading 3.2). The cell lines harboring edited EBV are helpful for genetic study of EBV. Third, we describe the procedures for the isolation of pure and infectious recombinant EBV created by CRISPR/Cas9 (see Subheading 3.3). The recombinant EBV can be produced and used for further infection experiments. Particularly, we supplied the protocol for insertion of the DsRed fluorescent marker to facilitate the recovery of mutant EBV. The methods described are generally applicable to the creation of both gene disruption and gene replacement in not only EBV but also other DNA viruses. 
Materials

Methods
The steps and criteria for optimal gRNA design are described based on using the deletion of the BART promoter in the EBV genome as an example. In our design, two gRNAs (pB1 and pB2) are employed to flank the whole BART promoter (pBART) region for deletion (see Note 1). The pSpCas9(BB)-2A-Puro (PX459)-based CRISPR/Cas9 system [13] , kindly provided by Dr. Feng Zhang, is accessed through Addgene (https://www.addgene. org/62988/), and is used in the following protocol.
1. The target region in the EBV genome is searched for a 19-bp sequence followed by the protospacer adjacent motif (PAM) NGG at the 3′ end. Two gRNAs flanking the target region are
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designed (see Note 2). For optimal gRNA binding, the GC content of the 19-bp target sequence is preferably within 40-60 %. The sequences of the pBART-gRNAs are as follows:
The target sequence is subjected to off-target analysis. Human and EBV genome sequences in the National Center for Biotechnology Information nucleotide databases are BLAST searched for matches to the 19-bp sequence together with NGG (e.g., TAATTGCAGTGGACCCCGGNGG for gRNA-B1). The stringency of the off-target analysis could be adjusted according to the purpose of the study. Only gRNAs with limited off-target hits are chosen. In our case, a sequence with a perfect match to PAM together with a match of >10 bp in the 19-bp region is avoided.
3. The 20-bp gRNA sequence with the first nucleotide being G is inserted into the PX459 vector. The addition of a G is required for optimal expression from the U6 promoter. The PX459 vector contains both gRNA and Cas9 expression cassettes.
4. The gRNA insert can be made by annealing the sense and antisense oligonucleotides. The annealed oligonucleotides are then inserted into the PX459 vector using the Zhang Lab General Cloning Protocol at the following website: (http:// www.addgene.org/crispr/zhang/).
We have used several EBV-infected epithelial cell lines for CRISPR/ Cas9 editing of the EBV genome [12] . These include the EBVinfected human embryonic kidney cell line HEK293-EBV, the human nasopharyngeal carcinoma cell lines HK1-EBV and C666-1, the human gastric adenocarcinoma cell line AGS-BX1 as well as the EBV-infected human telomerase reverse transcriptaseimmortalized normal nasopharyngeal epithelial cell line NP460-EBV. CRISPR/Cas9 editing of the EBV genome is performed directly inside these cells. Cells containing the edited virus are recovered by puromycin selection. The protocol should generally be amenable to all other EBV-infected cell lines that are not too difficult to transfect, including some B lymphocytic lines. 3. Harvest the cells 72 h post-transfection. Half of the cells are collected for genomic DNA extraction. Genomic DNA is extracted using a genomic DNA purification kit.
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4. Perform PCR using primers flanking the deleted region to screen for the desired CRISPR/Cas9-edited mutant virus. Successful editing will result in an additional amplicon of smaller size.
5. Transfer the remaining half of the cells into a 10-cm tissue culture dish. Twenty-four hours later, puromycin is added to select for the stable cells which contain the mutant virus (see Note 4).
6. Replace the drug-containing medium with fresh medium and cells after 48 h after puromycin treatment. Allow the cells to grow for 1 more week.
7. After 1 week, visible colonies of the selected cells should appear on the plate. Single colonies are picked by using filter paper (see Note 5).
8. Place a pre-soaked filter paper (with trypsin-EDTA) on top of the single cell colony at 37 °C for 3 min. The filter paper is then transferred with a pair of sterile forceps onto a 6-well tissue culture plate containing 2 ml of fresh culture medium. Shake the filter paper in the medium to make sure that the attached cells on the filter paper are detached into the well. The detached cells are allowed to recover and grow for 4 more days.
9. Verify the surviving clones by PCR as described in steps 3 and 4 above. PCR products derived from both edited and unedited EBV genomes are analyzed by agarose gel electrophoresis. In general, most of the surviving clones contain a mixture of wildtype and edited forms of EBV (see Note 6). In our pBART knockout experiment conducted in HEK293-EBV cells, 3 out of 50 clones were shown to be deprived of the unedited form of EBV carrying the pBART-deleted mutant virus only [12] .
10. Perform RT-PCR and Western blotting to verify the disruption of the target gene product in the puromycin-selected cell clones.
1. To generate an EBV-infected cell line that meets all the special requirements for the creation of a recombinant EBV by CRISPR/Cas9 editing, we have established HEK293-BX1 cells by coculturing HEK293 with Akata-BX1 cells. HEK293 cells are commonly used as EBV producer cells in BAC recombineering [6, 7] . They are highly susceptible to transfection and induction of lytic replication. Establishment of HEK293-BX1 cells for the conduction of CRISPR/Cas9 editing can therefore facilitate the construction, isolation, and production of recombinant EBV. On the other hand, insertion of a selectable marker or fluorescent reporter into the EBV genome can enable drug selection and mutant tracing, which are desirable for the isolation of recombinant EBV. To this end, we provide a protocol for the addition of DsRed fluorescent marker into EBV genome during CRISPR/Cas9 editing. This greatly facilitates tracing and recovery of mutant viruses. Additionally, we also describe
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an experimental approach to establish HEK293 producer cells of the mutant EBV through reinfection and sorting of DsRed 1. The pCMV-DsRed fragment containing the cytomegalovirus promoter (pCMV) was PCR-amplified from plasmid pDsRed2-C1 using KAPA HiFi DNA polymerase. Primers with an EBV homology arm of 50 bp are used for the amplification. For the knockout of pBART, the primers are 5′-ATGGTATTG
G T C G T C T T C T T C C C C T G C A G A G T A A T T G C A GTGGACCCCGGTGTTCTTTCCTGCGTTATCCC-3′ and 5′-TAGTGCCTACGTGACTCCCTGCTCCTGCCAGTT TCCCTTCGAGGTCTCCATAAGGGATTTTGC-3′.
The amplification primers for pCMV-DsRed are underlined and the EBV homology arms are located at the 5′ end.
3. The pCMV-DsRed fragment is gel-purified by using a highquality gel and PCR clean up kit. 4. Harvest the supernatants 6 days after transfection. All supernatants are filtered through a 1.20-μm syringe filter before infection.
5. Concentrate 40 ml of supernatant into 1 ml by using an Amicon ® Ultra-15 Centrifugal filter Ultracel ® -100 kDa. The Centricon is spun at 1400 × g for concentrating. It usually takes somewhere in the range of 30-45 min to concentrate 40 ml of supernatant to 1 ml. The concentrated virus can be stored at 4 °C for 1 week.
Grow approximately 2 × 10
5 HEK293 cells in a 6-well tissue culture plate 1 day before infection. 11. Test the recovered cells for recombinant virus production.
Usually the producer cells yield 1 × 10 5 to 1 × 10 6 /ml green Raji units of recombinant virus.
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12. Verify the genomic pattern of the recombinant virus by PCR and deep sequencing.
13. Once verified, the recombinant viruses are now ready for use in other infection assays.
Notes
1. Compared to the single gRNA approach, using two gRNAs to splice out the target region enhances the editing efficiency and facilitates the subsequent screening process.
2. For abrogation of protein expression, the start codon and the first exon should preferably be removed. For other regulatory elements, the complete target region can be deleted by two gRNAs.
3. HEK293-EBV, HK1-EBV and AGS-BX1 cells are transfected with GeneJuice (Novagen) in the ratio of 1 μg of DNA to 3 μl of GeneJuice. C666-1 and NP460-EBV are transfected with TransIT-Keratinocyte Transfection Reagent (Mirus) in the ratio of 1 μg of DNA to 3 μl of TransIT Reagent.
4. PX459 vector contains a puromycin selection marker. For HEK293-EBV cells, 3 μg/ml of puromycin is used. For NP460-EBV and AGS-BX1 cells, 2 μg/ml of puromycin is used. For C666-1 and HK1-EBV cells, 0.5 μg/ml of puromycin is used.
5. Filter papers are prepared by punches. The punched filter paper is autoclaved before use.
6. EBV maintains 5-100 copies of covalently closed circular genomic DNA in latently infected cells [11] . Inside a single cell, some copies of the EBV genome may escape from CRISPR/Cas9 editing. Extensive screening is required to obtain stable cells with the pure EBV mutant.
7. BZLF1 is the key transcriptional activator mediating the switch between latent and lytic replication of EBV. gp110 is the viral glycoprotein which remarkably enhances the ability of EBV to infect human cells [7] .
8. HEK293 cells are infected with a low multiplicity of infection (MOI) of EBV. Under low MOI conditions, most of the HEK293 cells will be infected with one particle of EBV, either a wild type or a recombinant.
